@article{10.37349/emd.2024.00062,
abstract = {Gout is common in people with chronic kidney disease and in general is sub-optimally managed. Lack of evidence due to the exclusion of people with chronic kidney disease from the majority of clinical trials, concerns about adverse effects and conflicting gout management guidelines all contribute to suboptimal management. Herein we review the evidence for the pharmacological treatment of gout, both flares and long-term urate-lowering, in people with concomitant chronic kidney disease.},
author = {Farquhar, Hamish and Gaffo, Angelo and Stamp, Lisa K.},
doi = {10.37349/emd.2024.00062},
journal = {Exploration of Musculoskeletal Diseases},
pages = {360--374},
title = {{Safety and efficacy of gout treatments in people with renal impairment}},
url = {https://www.explorationpub.com/Journals/emd/Article/100762},
volume = {2},
year = {2024},
number = {5}
}